Evidence map›Paper›PMID 31995589›Full record

ArticlePloS one2020

Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization.

Johannes Haubold, Johannes M Ludwig, Yan Li, Matthias Buechter, Axel Wetter, Lale Umutlu, Jens M Theysohn

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Johannes HauboldDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.ORCID 0000-0003-4843-5911
Johannes M LudwigDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Yan LiDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Matthias BuechterDepartment of Gastroenterology and Hepatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Axel WetterDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Lale UmutluDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Jens M TheysohnDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Essen University Hospital · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS: Thirty follow-up CT scans of 20 patients 6-12 weeks after Lipiodol-based cTACE, receiving a digital subtraction angiography at the same time, were analyzed. Reference for the detection of a residual tumor was the angiography, and a visible contrast enhancement was categorized as a residual tumor (n = 16 with residual tumor; n = 14 without residual tumor). The density of the iodine depositions was measured in all containing slices in non-contrast-, arterial- and portal venous-phase CT scans, with a slice thickness of 5.00 mm. The mean density of the iodine deposition during the portal venous phase was subtracted from the mean density of the arterial phase to calculate the density changes (a positive enhancement score represents washout in the portal venous phase). In addition, a quotient relating to the non-contrast measurement was evaluated.

resultsPatients with a residual tumor displayed significantly higher enhancement scores in favor of density reduction between the arterial and portal venous phases, compared to patients without a residual tumor (1.41 ± 3.59, n = 14 vs. -13.97 ± 2.88, n = 16; p-value < 0.01). Furthermore, 87.75% of patients with an enhancement score higher than -1.00 (n = 9) had a residual tumor, whereas 100.00% of patients with an enhancement score lower than -20.00 (n = 6) were shown to be tumor-free. The enhancement score quotient resulted in similar findings.

conclusionAfter cTACE in patients with hepatocellular carcinoma (HCC), the presence of a viable tumor correlated with enhancement scores based on the density measurements of iodine depositions in different phases of the CT scan. Low enhancement scores were associated with completely treated tumors and can aid the decision process to avoid possibly unnecessary angiographies.

Indexed as

AngiographyArteriesCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaEthiodized OilFemaleHumansIodineLiver NeoplasmsMaleNeoplasm, ResidualPortal VeinTomography, X-Ray ComputedContrast MediaEthiodized OilIodine

Identifiers

PMID31995589
PMCPMC6988944
OpenAlexW3004044081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.